Moon Surgical Appoints Fred Moll, MD, as Board Chair and Raises Additional $55.4 Million in New Funding with Leading Investors Sofinnova Partners and NVIDIA

May 17, 2023 8:00 AM

Fresh financing to accelerate the commercialization of Maestro SystemPARIS, FRANCE and SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2023 / Moon Surgical, a French-American pioneer in collaborative robotics, announced today that it has secured $55.4 million in additional funding to support the continued development and planned commercialization of its Maestro System. This most recent financing was co-led by Sofinnova Partners, through its...

Read more

Adolore Biotherapeutics Enters Exclusive License Agreement with University of Miami for Patents Protecting Non-Enzymatic Carbonic Anhydrase DNA Constructs and Their Protein Products and Uses

May 16, 2023 10:00 AM

Company developing next generation, disease-modifying, non-opioid analgesic gene therapies for the treatment of chronic painDELRAY BEACH, FL / ACCESSWIRE / May 16, 2023 / Adolore Biotherapeutics, Inc. ("Adolore" or the "Company") a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced it has entered into an exclusive licensing agreement with the University of Miami...

Read more

ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market

May 16, 2023 9:00 AM

BUFFALO, NY / ACCESSWIRE / May 16, 2023 / ZeptoMetrix® is excited to introduce PROtrol TM, a new line of products designed for antigen-based diagnostic methods. These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases. ZeptoMetrix logo PROtrol is the only whole organism reference material to provide...

Read more

tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

May 16, 2023 8:30 AM

KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and...

Read more

Owkin Receives European Medicines Agency Letter of Support for Innovative AI-Driven Approach to Oncology Trial Analysis

May 16, 2023 8:15 AM

EMA offers endorsement for AI optimization of clinical trials. Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma. Owkin to develop on-demand prognostic scores for other indications to further reduce clinical trial failure ratesPARIS, FRANCE / ACCESSWIRE / May 16, 2023 / AI Biotech Owkin, a leading provider of AI-powered solutions for drug discovery and clinical...

Read more

Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023

May 16, 2023 8:10 AM

COLLEGE STATION, TX / ACCESSWIRE / May 16, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced that the Company's wholly owned subsidiary, Virogentics (VIRO), has received the analysis report from the Bulgarian Academy of Sciences determining the protein concentration, native enzyme concentration and peptide analysis, and amino acid sequence...

Read more

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023 4:45 PM

JERUSALEM, ISRAEL / ACCESSWIRE / May 15, 2023 / (via IBN) -- BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the first quarter ended March 31, 2023, and provided a business update.First Quarter 2023 Financial SummaryR&D...

Read more

Ensysce Biosciences Reports First Quarter 2023 Financial Results

May 15, 2023 4:30 PM

Recently Completed Successful Ground-Breaking Study on Overdose ProtectionRecently Completed $7 Million Public OfferingSAN DIEGO, CA / ACCESSWIRE / May 15, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the first quarter of 2023 following the recently completed, successful...

Read more

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

May 15, 2023 4:00 PM

Presented updated results for treatment-naïve patients from Phase 1b study of gedatolisib at the ESMO Breast Cancer Annual Congress - median progression free survival (PFS) was 48.6 monthsPresented nonclinical prostate cancer data at ASCO GU Cancers Symposium demonstrating the superior therapeutic effect of gedatolisib compared to other PI3K, AKT, and mTOR inhibitors regardless of PTEN or P13K mutational statusPresented nonclinical...

Read more

Vaso Corporation Announces Financial Results for First Quarter 2023

May 15, 2023 9:00 AM

Revenue and Profitability Continued to Improve Year-over-yearPLAINVIEW, NY / ACCESSWIRE / May 15, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today reported its operating results for the three months ended March 31, 2023."The Company recorded a total revenue of $19.2 million for the first quarter of 2023, a growth of $2.2 million or 13.0% when compared to the same quarter last year. Quarterly gross profit reached $11.7 million, up by 19.9%...

Read more

EV Biologics Signs Exclusive Distribution Agreement for South America

May 15, 2023 8:00 AM

TAMPA, FL / ACCESSWIRE / May 15, 2023 / EV Biologics Corp (OTC PINK:YECO), today announced that it has signed an exclusive multi-year agreement with INNOVARE for distribution in South America.This agreement will facilitate the launch, in South America and the Caribbean, of EV Biologics regenerative health products, which are currently in production by its wholly owned subsidiary, EXCYTE.INNOVARE has long standing relationships and agreements in...

Read more

Manhattan BioSolutions, Inc. Enters into License Option Agreement with Wisconsin Alumni Research Foundation (WARF) for the RNA Nuclease Technology

May 15, 2023 7:00 AM

NEW YORK, NY / ACCESSWIRE / May 15, 2023 / Manhattan BioSolutions, Inc. ("Manhattan Bio"), an emerging biotechnology company developing new classes of precision biologics for the treatment of advanced cancers, today announced that it has entered into an exclusive option agreement with the Wisconsin Alumni Research Foundation (WARF) for the innovative pan-RNA degrader technologies (pRNAD) in oncology. The exclusive option agreement involves the...

Read more

AmplifyBio Adds Manufacturing Capabilities to Expand Service Portfolio

May 15, 2023 7:00 AM

AmplifyBio is adding manufacturing services, starting with cell therapy and plasmids, to its growing capabilities to support the safe development of advanced therapies.WEST JEFFERSON, OH / ACCESSWIRE / May 15, 2023 / AmplifyBio, an emerging hub for the commercialization of advanced therapies, has announced the addition of cell therapy and plasmid manufacturing capabilities to its leading portfolio of preclinical CRO and drug characterization...

Read more

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

May 12, 2023 4:40 PM

SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to...

Read more

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

May 12, 2023 12:30 PM

FRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of...

Read more

PinCell's Studies Open Up New Indications for Lead Candidate

May 12, 2023 9:30 AM

Two pre-clinical studies carried out by leading dermatologist Dr. Riichiro Abe, Professor and Chair of Dermatology at Niigata University, indicate that PC111 monoclonal antibody can ease Stevens-Johnson Syndrome by eliminating excess of circulating Fas ligandSevere form of SJS, called Toxic Epidermal Necrolysis, is often fatal and requires treatment in ICUs or burn unitsMILAN, ITALY / ACCESSWIRE / May 12, 2023 / PinCell, a biotechnology company...

Read more

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

May 12, 2023 6:15 AM

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian duration of response (DOR) was 46.9 monthsMINNEAPOLIS, MN / ACCESSWIRE / May 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023 4:30 PM

- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors- Ended the quarter with $12.0 million of cash to fund operations and drive pipeline forwardFRAMINGHAM, MA / ACCESSWIRE / May 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative...

Read more

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023 4:30 PM

TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2023 and provided an update on its business.During the fiscal second quarter, the company achieved two regulatory milestones, including an agreement with the U.S. Food and Drug Administration on the...

Read more

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023 4:05 PM

- Dermata raised $5 million gross proceeds from a public offering in March 2023 -- Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 -- FDA agreed that Dermata's chemistry, manufacturing, and control ("CMC") procedures support the initiation of Phase 3 studies of DMT310 for the treatment of acne -SAN DIEGO, CA / ACCESSWIRE / May 11, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the...

Read more